Justin Harper
Columbus, OHNPI 1215241534
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $149,324 of the $238,716 with a category attached, or 62.6%. Galderma Laboratories, L.p. accounts for 74.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $153,068 and has fallen 99.5% since, to $794 in 2025.
Across 362 payments — averaging $659.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$177K
- AbbVie$48K
- Ipsen Innovation$13K
- Merz North America, Inc.$136
- Endo Pharmaceuticals Inc.$96
What the payments were for
- Consulting fees$42,71418%
- Speaking & faculty fees$149,32463%
- Travel & lodging$39,31516%
- Food & beverage$7,3633%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 196 | $177,261 |
| AbbVie(2 entities) | 160 | $48,324 |
| Ipsen Innovation | 4 | $12,898 |
| Merz North America, Inc. | 1 | $136 |
| Endo Pharmaceuticals Inc. | 1 | $96 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX COSMETIC$38,358
- BOTOX$1,047
- XEOMIN$136
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.